Last update Oct. 30, 2023
Likely Compatibility
We do not have alternatives for Alvimopan.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Alvimopan in other languages or writings:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 6 | % |
Molecular weight | 425 | daltons |
Protein Binding | 80 - 94 | % |
VD | 0.42 (0.3 - 0.6) | l/Kg |
pKa | 3.71 | - |
Tmax | 2 | hours |
T½ | 10 - 18 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Alvimopan is an opioid antagonist used to reduce the healing time of postoperative ileus of the upper or lower gastrointestinal tract following surgical procedures involving bowel resection with primary anastomosis. Oral administration twice daily for 7 days after surgery.
At the time of the last update, we found no published data on its excretion in breast milk.
Its large volume of distribution, high percentage of binding to plasma proteins and moderately high molecular weight make it unlikely to pass into breast milk in clinically significant quantities.
Its very low oral bioavailability makes it difficult to pass into infant plasma from ingested breast milk.